Beyond Therapies
Tap into our comprehensive expertise across diverse therapy areas. We specialise in conducting research for both clinically complex and specialist indication areas, as well as general, primary care indications.
Our top therapy areas to work in are:
Navigate the complexities of oncology with strategic insight.
Oncology is fast-moving, competitive, and increasingly complex. There’s always something new - from novel modalities that bring fresh practical and logistical considerations, to evolving biomarkers that redefine how patients are selected and treated.
At the same time, as brands stretch across indications, messaging and positioning need to work in harmony across the full portfolio. All of this makes it essential to work with a partner who can see, and make sense of, the full landscape.
Stay ahead in the dynamic oncology landscape with deep scientific understanding, sharp awareness of market dynamics, technical fluency across stakeholder groups, and industry-leading moderation. This combination allows us to get to the heart of the challenge and deliver insights that drive confident decision-making.
ASCO 2025: Sneak Peek at Key Themes for This Year’s Conference
As ASCO 2025 approaches, all eyes are on the pivotal trials that could shift standards, reshape narratives, and spark new questions for oncology strategy. From groundbreaking trials in mBC to paradigm-challenging immunotherapy in colon cancer, this year’s line-up is...
ASCO GU 2025: Key takeaways and emerging trends that will impact patient management
The ASCO GU 2025 Symposium delivered fresh insights into the evolving landscape of genitourinary (GU) cancer care. From breakthroughs in prostate, bladder, and renal cell carcinoma (RCC) to a growing focus on health disparities and the increasing value of ctDNA, here...
Lung Cancer Awareness Month 2024
It’s Lung Cancer Awareness Month, which made us reflect on our recent interactions with patients …. Understanding the Journey of NSCLC Patients: A Call to Action In our extensive work with non-small cell lung cancer (NSCLC), we’ve learned one undeniable truth: there...
Elevating Excellence: Expanding Our Oncology Team
Oncology has always been a key area of focus for us. As the demand for our oncology expertise continues to surge, we are thrilled to announce the expansion of our devoted team. Within the fabric of our expanding team, a key objective is to establish a dedicated group...
Navigating 2024’s Oncology Hot Topics
As we embark on a new year, our oncology team has been busy crafting predictions to guide us through 2024. Continue reading to discover the key trends and game-changers our team have selected. Will it be a green light for CAR-T ambitions, or a U-turn? Stepping into...
Top takeouts from ESMO 2023
Last week, our Research Directors, Siobhan Davies and Lindsay Widger, landed back in the UK from the ESMO Congress 2023 in Madrid. The conference brought together likeminded passionate professionals in oncology to discuss and digest the very latest developments. ESMO...
ESMO Congress Madrid 2023: What’s in store?
ESMO 2023 Madrid beckons, in just over a week (20th -24th October). Our Research Directors, Lindsay Widger and Siobhan Davies, will be in attendance reporting back on the hottest topics and connecting with like-minded oncology experts to discuss the implications as...
ASCO 2023: Our key themes
A few weeks ago, we attended the ASCO Annual Meeting which brought the latest oncology developments. The meeting provides an exceptional opportunity to connect with one of the largest, most diverse audiences in global cancer care and we were extremely proud to be a...
Neoadjuvant Chemo-IO – a new standard for resectable NSCLC?
12 months ago, at ESMO 2021, the oncology community was asked, “Are we ready to consider chemotherapy + checkpoint inhibitor as the preferred option in the neoadjuvant setting?”. At that time, 71% felt the available efficacy data was not sufficient to implement...
Expert insights into future opportunities in immuno-oncology
It is widely accepted that the use of immunotherapy agents has been one of the major advances in oncology over recent years. But what further changes can we expect as the area develops in the next few years, and what does that mean for pharma? To look further into...
Oncology Trends, Views and Perspectives from Beyond Blue
What are the leading oncology issues and drug development trends, outside of reimbursement/drug access? What is the impact of COVID–19 across oncology? How can we use market research methods to maximise stakeholder insights on future oncology drug development,...
Clear thinking for complex neurology challenges
Neurology is often defined by complex, progressive conditions where the goal is not cure, but slowing decline. This creates commercialisation challenges rooted in contradiction: the value of disease modification lies in early intervention, and yet at this stage symptoms may be subtle, intermittent or management appears straightforward.
The unmet need suggests that any slowing of decline should be meaningful, and yet when benefits are hard to see, building conviction among HCPs, families, and systems becomes a challenge.
At Beyond Blue, we understand the tension between evolving science and human behaviour. Complex journeys, human decisions, evolving science — these lie at the heart of commercialising neurology.
Explore how patients, caregivers, and clinicians perceive risk, progression, and value, and uncover what it takes to shift behaviour when benefits aren’t immediately visible, and how to build belief in disease-modifying therapies early, when they matter most.
See our latest thinking for more insights!
Connect the dots across Cardiorenalmetabolic (CVRM)
CVRM is undergoing a transformation. With rapid innovation across heart failure, diabetes, CKD, obesity, and beyond, the opportunity is growing - but so is the complexity.
It’s no longer a set of siloed indications, but an interconnected ecosystem with unique challenges: the breadth of the competitor landscape, increasingly dynamic patient segmentation, and shared care models that can blur lines of responsibility.
Get insights to connect the dots across therapeutic areas and specialties, decode real-world patient journeys, and track the shifting competitive landscape - so your strategy is always grounded in clarity, not guesswork.
See our latest thinking for more insights!
Excel in radiology research with unparallelled expertise
Radiology doesn’t sit neatly within traditional pharma. It’s a space where technology, diagnostics, and therapeutics converge - spanning med-tech devices, contrast agents, and fast-moving developments in software and AI.
But more than that, it’s a discipline built on workflows, efficiencies, and system-wide impact - not just clinical outcomes.
Leverage our extensive expertise across in the science, technology, and stakeholder landscape of radiology - so insights don’t just answer questions, they drive smarter decisions.
See our latest thinking for more insights!
Navigate the complexities of oncology with strategic insight.
Oncology is fast-moving, competitive, and increasingly complex. There’s always something new - from novel modalities that bring fresh practical and logistical considerations, to evolving biomarkers that redefine how patients are selected and treated.
At the same time, as brands stretch across indications, messaging and positioning need to work in harmony across the full portfolio. All of this makes it essential to work with a partner who can see, and make sense of, the full landscape.
Stay ahead in the dynamic oncology landscape with deep scientific understanding, sharp awareness of market dynamics, technical fluency across stakeholder groups, and industry-leading moderation. This combination allows us to get to the heart of the challenge and deliver insights that drive confident decision-making.
Check out our deep dive case study click below.
ASCO 2025: Sneak Peek at Key Themes for This Year’s Conference
As ASCO 2025 approaches, all eyes are on the pivotal trials that could shift standards, reshape narratives, and spark new questions for oncology strategy. From groundbreaking trials in mBC to paradigm-challenging immunotherapy in colon cancer, this year’s line-up is...
ASCO GU 2025: Key takeaways and emerging trends that will impact patient management
The ASCO GU 2025 Symposium delivered fresh insights into the evolving landscape of genitourinary (GU) cancer care. From breakthroughs in prostate, bladder, and renal cell carcinoma (RCC) to a growing focus on health disparities and the increasing value of ctDNA, here...
Lung Cancer Awareness Month 2024
It’s Lung Cancer Awareness Month, which made us reflect on our recent interactions with patients …. Understanding the Journey of NSCLC Patients: A Call to Action In our extensive work with non-small cell lung cancer (NSCLC), we’ve learned one undeniable truth: there...
Elevating Excellence: Expanding Our Oncology Team
Oncology has always been a key area of focus for us. As the demand for our oncology expertise continues to surge, we are thrilled to announce the expansion of our devoted team. Within the fabric of our expanding team, a key objective is to establish a dedicated group...
Navigating 2024’s Oncology Hot Topics
As we embark on a new year, our oncology team has been busy crafting predictions to guide us through 2024. Continue reading to discover the key trends and game-changers our team have selected. Will it be a green light for CAR-T ambitions, or a U-turn? Stepping into...
Top takeouts from ESMO 2023
Last week, our Research Directors, Siobhan Davies and Lindsay Widger, landed back in the UK from the ESMO Congress 2023 in Madrid. The conference brought together likeminded passionate professionals in oncology to discuss and digest the very latest developments. ESMO...
ESMO Congress Madrid 2023: What’s in store?
ESMO 2023 Madrid beckons, in just over a week (20th -24th October). Our Research Directors, Lindsay Widger and Siobhan Davies, will be in attendance reporting back on the hottest topics and connecting with like-minded oncology experts to discuss the implications as...
ASCO 2023: Our key themes
A few weeks ago, we attended the ASCO Annual Meeting which brought the latest oncology developments. The meeting provides an exceptional opportunity to connect with one of the largest, most diverse audiences in global cancer care and we were extremely proud to be a...
Neoadjuvant Chemo-IO – a new standard for resectable NSCLC?
12 months ago, at ESMO 2021, the oncology community was asked, “Are we ready to consider chemotherapy + checkpoint inhibitor as the preferred option in the neoadjuvant setting?”. At that time, 71% felt the available efficacy data was not sufficient to implement...
Expert insights into future opportunities in immuno-oncology
It is widely accepted that the use of immunotherapy agents has been one of the major advances in oncology over recent years. But what further changes can we expect as the area develops in the next few years, and what does that mean for pharma? To look further into...
Clear thinking for complex neurology challenges
Neurology is often defined by complex, progressive conditions where the goal is not cure, but slowing decline. This creates commercialisation challenges rooted in contradiction: the value of disease modification lies in early intervention, and yet at this stage symptoms may be subtle, intermittent or management appears straightforward.
The unmet need suggests that any slowing of decline should be meaningful, and yet when benefits are hard to see, building conviction among HCPs, families, and systems becomes a challenge.
At Beyond Blue, we understand the tension between evolving science and human behaviour. Complex journeys, human decisions, evolving science — these lie at the heart of commercialising neurology.
Explore how patients, caregivers, and clinicians perceive risk, progression, and value, and uncover what it takes to shift behaviour when benefits aren’t immediately visible, and how to build belief in disease-modifying therapies early, when they matter most.
See our latest thinking for more insights!
Connect the dots across Cardiorenalmetabolic (CVRM)
CVRM is undergoing a transformation. With rapid innovation across heart failure, diabetes, CKD, obesity, and beyond, the opportunity is growing - but so is the complexity.
It’s no longer a set of siloed indications, but an interconnected ecosystem with unique challenges: the breadth of the competitor landscape, increasingly dynamic patient segmentation, and shared care models that can blur lines of responsibility.
Get insights to connect the dots across therapeutic areas and specialties, decode real-world patient journeys, and track the shifting competitive landscape - so your strategy is always grounded in clarity, not guesswork.
See our latest thinking for more insights!
Excel in radiology research with unparallelled expertise
Radiology doesn’t sit neatly within traditional pharma. It’s a space where technology, diagnostics, and therapeutics converge - spanning med-tech devices, contrast agents, and fast-moving developments in software and AI.
But more than that, it’s a discipline built on workflows, efficiencies, and system-wide impact - not just clinical outcomes.
Leverage our extensive expertise across in the science, technology, and stakeholder landscape of radiology - so insights don’t just answer questions, they drive smarter decisions.